NEW DELHI, India – November 26, 2025 – Dr. Lal PathLabs Ltd. (BSE: 539524, NSE: LALPATHLAB), a leading diagnostic service provider in India, today announced a significant advancement in the domestic healthcare landscape with the launch of the country’s first Comprehensive Complement Testing Laboratory. This strategic initiative establishes a new, specialized diagnostic hub aimed at delivering faster and more accurate diagnosis of complex autoimmune, renal, and immunological disorders.
The launch comes at a critical time, as a 2024 study highlighted a 30% increase in autoimmune disorders among the Indian population post-pandemic, with the most pronounced rise observed in the 31-45 age demographic<sup>1</sup>. Furthermore, data presented at IRACON 2025 indicated that nearly 70% of autoimmune patients in India are women, underscoring a significant and specific healthcare need<sup>2</sup>.
Addressing a Critical Diagnostic Gap
Autoimmune diseases often present a diagnostic challenge, beginning with non-specific symptoms like persistent fever, joint pain, fatigue, and kidney issues. This can lead to prolonged patient journeys and delayed treatment. The newly launched Complement Lab is designed to directly address this gap.
The complement system is a vital part of the body’s immune defenses. Its dysfunction—either underactive or overactive—is implicated in a range of serious conditions, including:
- Systemic Lupus Erythematosus (Lupus)
- C3 Glomerulopathy and Atypical Haemolytic Uremic Syndrome (aHUS)
- Vasculitis
- Rheumatoid Arthritis
- Severe or Recurrent Infections
- Transplant Rejection
The new laboratory will offer a comprehensive suite of tests, including specialized assays like C1q, C5, Factor B, Factor H antibody, AH50, and C1 INH functional, many of which are being made available in India for the very first time. By measuring key immune proteins, these tests provide clinicians with crucial insights to determine whether a patient’s immune response is malfunctioning, enabling earlier and more precise intervention.
Management Commentary
“Complement testing has long been underrepresented in India’s diagnostic landscape,” said Dr. Vandana Lal, Executive Director of Dr. Lal PathLabs. “By introducing functional and antibody-based complement assays, many for the first time in the country, we are enabling earlier and more precise insights into immune-mediated disease. This bridges the gap between research and routine clinical care.”
Mr. Shankha Banerjee, CEO of Dr. Lal PathLabs, added, “As a pioneer in specialized diagnostics, we are proud to offer India’s first comprehensive complement testing platform. This marks a major step toward faster diagnosis, better treatment decisions, and improved outcomes for millions living with autoimmune and kidney diseases. This expansion into high-end specialized testing aligns with our strategy to enhance our service portfolio and drive long-term growth.”
Operational Excellence and Patient Impact
The state-of-the-art laboratory is equipped with advanced immunoturbidimetric and ELISA platforms and operates under the stringent quality standards of its CAP and NABL accreditations. For patients, this translates to greater diagnostic clarity, potentially leading to better treatment outcomes, reduced long-term healthcare costs, and an improved quality of life through timely and accurate disease management.
About Dr. Lal PathLabs Limited
Dr. Lal PathLabs is one of India’s leading providers of diagnostic and related healthcare tests and services. As of March 31, 2025, the company operates an integrated network of 298 clinical laboratories, 6,607 Patient Service Centers (PSCs), and 12,365 Pick-up Points (PUPs) across the nation. Its services are utilized by individual patients, hospitals, healthcare providers, and corporate customers.
https://nsearchives.nseindia.com/corporate/LALPATHLAB_26112025100307_Pressrelease26112025.pdf
Useful Websites for Investors
For comprehensive financial and market information, investors are advised to refer to official sources:
Disclaimer
Not a SEBI Registered Analyst
I am not a SEBI Registered Investment Adviser or Research Analyst. All information shared is for educational and informational purposes only and is not intended as a substitute for professional financial advice. All opinions expressed herein are based on my personal observations and research. They do not constitute a recommendation or a solicitation to buy, sell, or hold any security. Investments in the securities market are subject to market risks. The value of investments may go up or down. Past performance is not indicative of future results.
You are solely responsible for your own investment decisions. You should conduct your own research and consult with a qualified financial advisor before making any investment based on the information provided here.
I may or may not hold positions in the securities mentioned. This is a personal blog/platform, and I have no relationship with the companies mentioned unless explicitly stated.